retatrutide autoimmune Side Effects: What Patients Should Know Weight loss with retatrutide as

Eli Lilly, however, is still awaiting FDA approval for its oral GLP-1 candidate

Long term data from trials such as STEP and SUSTAIN show that gallbladder events are most common in the first year of treatment when weight loss is most rapid

PMID 19135374

Additionally, the LEADER study reported a post-hoc analysis in patients with polyvascular disease (defined as atherosclerosis in two or more of the following vasculature territories: ocular, coronary arteries, cerebral arteries or arteries peripheral), in which they did not observe significant differences in the risk of non-fatal stroke in the liraglutide group versus placebo [63]